Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis
Makoto Naganuma,Shinya Sugimoto,Keiichi Mitsuyama,Taku Kobayashi,Naoki Yoshimura,Hidehisa Ohi,Shinji Tanaka,Akira Andoh,Naoki Ohmiya,Keiichiro Saigusa,Takayuki Yamamoto,Yuichi Morohoshi,Hitoshi Ichikawa,Katsuyoshi Matsuoka,Tadakazu Hisamatsu,Kenji Watanabe,Shinta Mizuno,Wataru Suda,Masahira Hattori,Shinji Fukuda,Akiyoshi Hirayama,Takayuki Abe,Mamoru Watanabe,Toshifumi Hibi,Yasuo Suzuki,Takanori Kanai,INDIGO Study Group,Yoshihiro Nakazato,Tomohiro Fukuda,Toshiaki Teratani,Haruhiko Ogata,Yasushi Iwao,Hiroshi Yamasaki,Takahiko Toyonaga,Masaru Nakano,Yoichi Sameshima,Ryohei Hayashi,Yoshitaka Ueno,Shigeki Bamba,Atsushi Nakazawa,Yuji Koike,Jin Imai,Takahiro Shimoyama,Ken Takeuchi,Mitsuo Nagasaka,Atsuo Kitano,Shinya Ashizuka,Haruhiko Inatsu,Kei Onodera,Hiroshi Nakase,Kazuya Kitamura,Kentaro Ikeya,Hiroyuki Hanai,Chikako Watanabe,Ryota Hokari,Fumihito Hirai,Yuji Naito,Namiko Hoshi,Fukunori Kinjo,Yo Ishiguro,Makoto Sasaki,Takayuki Matsumoto,Fumiya Sano,Rachel Roberts
DOI: https://doi.org/10.1053/j.gastro.2017.11.024
IF: 29.4
Gastroenterology
Abstract:Background & aims: Indigo naturalis (IN) is a traditional Chinese medicine that contains ligands for the aryl hydrocarbon receptor and promotes regeneration of the mucosa by inducing production of interleukin 22. IN might induce mucosal healing in patients with ulcerative colitis (UC). We performed a randomized controlled trial to investigate the safety and efficacy of IN in patients with UC. Methods: We performed a multicenter, double-blind trial evaluating the safety of 86 patients in Japan with active UC (Mayo scores of 6 or more), enrolled from March 30 through December 27, 2016. Patients were randomly assigned to groups and given a daily dose of 0.5, 1.0, or 2.0 g IN or placebo (1:1:1:1 ratio) for 8 weeks. The primary endpoint was the rate of clinical response at week 8, defined as a 3-point decrease in the Mayo score and a decrease of at least 30% from baseline, with a decrease of at least 1 point for the rectal bleeding subscore or absolute rectal bleeding score of 0-1. The main secondary endpoint was the rate of clinical remission at week 8, defined as a Mayo score or ≤2 and no subscores with a value >1. Mucosal healing was also assessed at week 8. Results: The trial was terminated because of an external reason: a report of pulmonary arterial hypertension in a patient who used self-purchased IN for 6 months. In the intent-to-treat analysis, we observed a significant, dose-dependent linear trend in proportions of patients with clinical responses (13.6% with a clinical response to placebo; 69.6% to 0.5 g IN; 75.0% to 1.0 g IN; and 81.0% to 2.0 g IN) (Cochran-Armitage trend test P < .0001 compared with placebo). Proportions of patients in clinical remission at week 8 were significantly higher in the 1.0 g IN group (55.0%, P = .0004) and the 2.0 g IN group (38.1%, (P = .0093) than in the placebo group (4.5%). Proportions of patients with mucosal healing were 13.6% in the placebo group, 56.5% in the 0.5 g IN group, 60.0% in the 1.0 g IN group, and 47.6% in the 2.0 g IN group (P = .0278 compared with placebo). Although mild liver dysfunction was observed in 10 patients who received IN, no serious adverse events were observed. Conclusions: In a randomized, placebo-controlled trial, we found 8 weeks of IN (0.5-2.0 g per day) to be effective in inducing a clinical response in patients with UC. However, IN should not yet be used because of the potential for adverse effects, including pulmonary arterial hypertension. Clinical Trials Registry no: UMIN000021439 (http://www.umin.ac.jp/ctr/).